Beyond the Cargo Limit: Meet AAVantgarde Bio
The Milan-based startup bringing a dual strategy to gene therapy’s biggest delivery challengery week,
Another weekend, another startup to watch 👀!
As requested by you, this Friday I'm spotlighting another gene therapy company tackling the same core challenge as SpliceBio: the size limit of AAV vectors when delivering large genes.
🧬 Meet AAVantgarde Bio (Milan, Italy):
A startup on a mission to expand what’s possible in gene therapy by overcoming AAV’s packaging limitations.
🤔 What sets AAVantgarde apart from SpliceBio is their 𝗱𝘂𝗮𝗹 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗼𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝗔𝗔𝗩’𝘀 𝗰𝗮𝗿𝗴𝗼 𝗹𝗶𝗺𝗶𝘁:
👉 SpliceBio focuses on 𝗶𝗻𝘁𝗲𝗶𝗻-𝗺𝗲𝗱𝗶𝗮𝘁𝗲𝗱 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝘀𝗽𝗹𝗶𝗰𝗶𝗻𝗴 to reassemble large proteins inside the cell
👉 AAVantgarde 𝗰𝗼𝗺𝗯𝗶𝗻𝗲𝘀 𝘁𝗵𝗶𝘀 𝘄𝗶𝘁𝗵 𝗮 𝗗𝗡𝗔-𝗹𝗲𝘃𝗲𝗹 𝗿𝗲𝗰𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 - allowing them to tailor their technology depending on the gene and disease. This flexibility could give them an edge in tackling a broader range of large-gene disorders.
Definitely another one to keep under your radar!
👇
_________________________________________
👋 Hi, I’m Cecilia - academic researcher turned biotech recruiter, now mentor and founder of The Catalytic Site.
🧪 Are you an academic interested in biotech? Follow me for insights and resources to help you make the move.
♻️ Grab my free biotech-optimized 𝗖𝗩 𝗧𝗲𝗺𝗽𝗹𝗮𝘁𝗲 (https://lnkd.in/gA7xTrHa)